Stock Analysis on Net
Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Common-Size Income Statement 
Quarterly Data

Moderna Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cost of sales -28.24 -62.50 -57.49 -33.26 -127.55 -249.49 -43.33 -39.47 -35.26 -30.48 -17.16 -13.73 -15.01 -17.87 -11.14 -3.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Gross profit (loss) 71.76% 37.50% 42.51% 66.74% -27.55% -149.49% 56.67% 60.53% 64.74% 69.52% 82.84% 86.27% 84.99% 82.13% 88.86% 96.03% — — — — — — —
Other revenue 2.31 30.98 0.00 0.64 4.21 17.41 1.86 4.63 7.82 4.81 2.38 3.98 3.31 3.74 11.77 185.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Research and development -62.47 -663.59 -636.53 -50.34 -66.02 -391.81 -61.87 -24.92 -26.28 -15.67 -9.35 -9.34 -10.83 -10.03 -23.14 -379.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Selling, general and administrative -15.44 -145.65 -164.07 -16.83 -25.16 -113.31 -16.68 -7.72 -8.91 -4.66 -4.52 -2.90 -3.49 -2.88 -4.44 -39.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income (loss) from operations -3.85% -740.76% -758.08% 0.21% -114.51% -637.20% -20.02% 32.52% 37.37% 54.01% 71.34% 78.01% 73.97% 72.96% 73.05% -137.61% — — — — — — —
Interest income 5.66 60.33 71.86 3.69 5.98 35.49 5.96 1.79 1.86 0.88 0.25 0.10 0.08 0.07 0.23 2.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other income (expense), net -0.66 -14.67 -11.38 -1.40 -2.90 4.78 -2.63 -0.25 -0.22 -0.29 -0.22 -0.10 -0.21 -0.05 -0.58 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income (loss) before income taxes 1.15% -695.11% -697.60% 2.51% -111.44% -596.93% -16.68% 34.06% 39.01% 54.60% 71.38% 78.01% 73.85% 72.98% 72.71% -135.59% — — — — — — —
(Provision for) benefit from income taxes -0.44 0.00 -5.99 5.26 -95.16 125.94 21.01 -3.91 -5.58 -6.11 -9.65 -7.82 -4.55 -6.74 -2.25 -0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income (loss) 0.71% -695.11% -703.59% 7.77% -206.60% -470.99% 4.32% 30.15% 33.43% 48.49% 61.72% 70.19% 69.29% 66.24% 70.46% -136.33% — — — — — — —

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Moderna Inc. income (loss) from operations as a percentage of net product sales increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Moderna Inc. income (loss) before income taxes as a percentage of net product sales increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net Income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Moderna Inc. net Income (loss) as a percentage of net product sales increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.